Alpaca nanobodies neutralize SARS-CoV-2 in vitro

The immense human toll exerted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-mediated pandemic of coronavirus disease 2019 (COVID-19) can be arrested only by the induction of population immunity against the virus. The only feasible route appears to be via vaccination. However, pending the global availability of highly effective vaccines, therapeutics that can reverse the severe and life-threatening clinical features of SARS-CoV-2 infection continue to be the focus of most research.

A new preprint research paper posted to the bioRxiv* server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

Targeting the SARS-CoV-2 RBD

SARS-CoV-2 accomplishes entry into and infection of the host cell by binding to ACE2 on the cell surface, via the RBD on the viral spike protein. The RBD is the target of 90% of currently available therapeutic antibodies and antibodies elicited by most current vaccines.

Isolation of nanobodies to SARS-CoV-2 RBD

While convalescent plasma and monoclonal antibodies directed against the virus have been used in therapeutic trials, the current study is based on the efficacy of an antibody fragment obtained from the immunoglobulins elicited from camelids, namely, alpacas. These fragments are called VHH or nanobodies and hold great promise for the treatment of COVID-19.

The advantages of VHH include the inexpensive manufacturing process, higher penetration into tissues, and easier modification to form multivalent antibodies, or antibodies capable of recognizing and binding to multiple specific antigens. They are also ideal for treating lung disease as they are small enough to be directly injected or infused into the lungs, with high solubility and stability.

In the current study, the researchers report a series of novel nanobodies against SARS-CoV-2. These were isolated from immunized alpacas that had received three doses of recombinant purified SARS-CoV-2 RBD. The seven RBD-specific nanobodies were identified in a phage display screen.

Fusion with Fc

The researchers also modified the nanobodies by incorporating them into immunoglobulin G1 (IgG1), fusing them with the Fc portion. This resulted in the formation of homodimers. Together with the higher molecular weight, the bivalent nature of these chimeras led to a marked improvement in RBD binding affinity. In fact, it rose even above that reported for some monoclonal antibodies isolated from convalescent COVID-19 patients.

Neutralization efficacy

Neutralization efficacy also improved to the nanomolar range. The researchers observed that compared to the use of monovalent Nbs, the homodimers caused higher neutralization of RBD-ACE2 binding, with the 50% inhibitory concentration (IC50) being reduced 5-90 times.

The binding activity of the recently emerged N501Y variant for ACE2 was higher relative to the ancestral RBD, as expected, but all seven nanobodies made no distinction between the original and mutant RBD in their binding.

Heterobivalent antibodies have increased affinity

The study also demonstrated the favorable effects of fusing two nanobodies that had non-overlapping epitopes to form heterodimers. The linkage was achieved via a flexible linker. These bivalent antibodies were thus able to bind different sites on the RBD, namely, aRBD-2-5 and aRBD aRBD-2-7. The binding affinity of these antibodies for the RBD was still higher, as was the neutralizing potency.

While six nanobodies effectively neutralized the RBD-ACE2 interaction, one, called aRBD-7, showed weak blocking ability despite a high binding affinity for RBD. The investigators attributed this to the binding of different nanobodies to different RBD epitopes, which results in varying degrees of the blockade of RBD-ACE2 binding.

For heterodimers aRBD-2-5 and aRBD aRBD-2-7, the researchers measured a 50% neutralization dose (ND50) of 7 was ~0.043 nM) and ~0.1 0.111 nM, respectively. The fusion of these nanobodies with Fc did not push up the neutralization potency any higher.

It was interesting to observe that the incorporation of the weak neutralizing nanobody aRBD-7 into a homodimer or into a heterodimer led to a 75-fold improvement in neutralization. This is caused by the increase in binding affinity due to dimer formation, as well as a greater steric hindrance because of the larger molecular size.

What are the implications?

The nanobodies identified in the current study were extremely stable and had a high binding affinity for SARS-CoV-2 RBD. Six of the identified nanobodies were able to neutralize spike-ACE2 binding.

The researchers note that the formation of heterodimers led to a neutralization potency superior to other nanobodies reported earlier, as well as some monoclonal antibodies. A multivalent nanobody has been reported in recent research, which has even higher neutralization efficacy.

Due to their small size, high solubility and stability, [nanobodies] are particularly well suited for pulmonary delivery and more amenable to engineer into multivalent formats, compared to the conventional antibody.”

The alpaca VHH is significantly homologous with humans' VH3, leading to low immunogenicity in the latter. The natural nanobodies with high RBD binding affinity and potent neutralization efficacy against RBD-ACE2 binding, as well as the engineered hetero-bivalent nanobodies with high neutralization potency, are promising leads for further development of therapeutic antivirals against SARS-CoV-2, as well as diagnostic tests.

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2021, February 04). Alpaca nanobodies neutralize SARS-CoV-2 in vitro. News-Medical. Retrieved on October 02, 2022 from

  • MLA

    Thomas, Liji. "Alpaca nanobodies neutralize SARS-CoV-2 in vitro". News-Medical. 02 October 2022. <>.

  • Chicago

    Thomas, Liji. "Alpaca nanobodies neutralize SARS-CoV-2 in vitro". News-Medical. (accessed October 02, 2022).

  • Harvard

    Thomas, Liji. 2021. Alpaca nanobodies neutralize SARS-CoV-2 in vitro. News-Medical, viewed 02 October 2022,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
SARS-CoV-2 generates amyloid in cerebral spinal fluid